Biocon’s subsidiary -- Biocon Biologics has executed the settlement and license agreement with Amgen Inc. that clears the path for the commercialization of Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq) in the United States (U.S.). Biocon Biologics and Amgen have executed the settlement agreement to resolve the pending patent litigation at the United States District Court for the District of New Jersey. The agreement enables Biocon Biologics to launch BOSAYA and AUKELSO in the U.S. from October 1, 2025. Biocon Biologics is a fully integrated global biosimilars company.
Bosaya 60 mg/mL injection in a single-dose prefilled syringe (PFS) and Aukelso 120 mg/1.7 mL, 70 mg/mL injection for subcutaneous use in a single-dose vial, are biosimilars to Amgen’s Prolia and Xgeva, respectively. These products are used in the treatment of osteoporosis and cancer-related bone conditions.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
